SLRN News ACELYRIN, INC. Common Stock (SLRN) News Latest SLRN News Stocks$SLRN stock is up 11% today. Here's what we see in our data.1 day ago • Quiver Quantitative Stocks Insider Sale: Chief Executive Officer of $SLRN Sells 17,986 Shares Mar 19, 2025 • Quiver Qua...
SLRN News ACELYRIN, INC. Common Stock (SLRN) News Latest SLRN News Stocks$SLRN stock is up 11% today. Here's what we see in our data.5 days ago • Quiver Quantitative Stocks Insider Sale: Chief Executive Officer of $SLRN Sells 17,986 Shares Mar 19, 2025 • Quiver ...
Alumis与ACELYRIN的联合正式代理声明,关于拟议合并 >ALMS SLRN Alumis与ACELYRIN联合提交的提案合并的最终代理声明 >ALMS 道琼斯04:36 内部股权出售震撼了ACELYRIN公司。 TipRanks03/20 10:06 Acelyrin | 10-K:2024财年年报 美股SEC公告03/20 04:05· 业绩公告 Acelyrin采取毒丸策略,唐资本伙伴建立股份 丹尼·...
雷递网 雷建平 5月4日 生物技术公司Acelyrin(股票代码为:SLRN)将于近期在纳斯达克上市。 Acelyrin发行区间为16美元到18美元,发行2060万股,最高可募资3.7亿美元,估值可超过20亿美元。 年亏损6477万美元 Acelyrin致力于自身免疫性疾病治疗,Acelyrin正招募Izkibep 参与一项治疗葡萄膜炎(一种威胁视力的眼内炎症)的关键...
去年12月,自免公司Acelyrin因CRO公司弄错临床试验药物剂量而备受关注。然而,其股价在经历9月的大跌后,继续下跌。如今,三个多月过去了,终于迎来了临床试验的积极进展。 3月11日,周一,Acelyrin公布了其IL-17A抑制剂izokibep针对银屑病关节炎(PsA)的2b/3期临床数据。结果显示,主要终点16周的ACR50达到了统计学显著。
LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on its izokibep clinical developm...
Investing.com — Alumis Inc. (NASDAQ: ALMS)和ACELYRIN, INC. (NASDAQ: SLRN)今日宣布修订其合并协议条款,增加ACELYRIN股东在合并后公司的所有权比例。根据修订后的交换比率,ACELYRIN股东将获得约48%的所有权,而Alumis股东将拥有约52%的完全稀释后所有权。根据InvestingPro数据显示,Alumis进入此次合并时拥有强劲...
News & Analysis Featured Article Highest-Paid CEOs in 2024 You'll be shocked to learn how much these executives earn annually. Catherine Brock | Nov 5, 2024 Featured Article Why Acelyrin Stock Plummeted 59% This Week The recently public biopharma company announced disappointing results from ...